ASTM News Alert Aastrom Biosciences (ASTM) 2.77 02/14/2015 1

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 8:55 PM

Aastrom Biosciences (ASTM) 2.77 $ASTM

Aastrom Biosciences announces change in name and ticker symbol upon shareholders approval
M2 - Wed Nov 26, 6:54AM CST
Cellular therapies company Aastrom Biosciences (NasdaqCM:ASTM) reported on Tuesday a change in its corporate name to Vericel (NASDAQ:VCEL) with immediate effect.
VCEL: 3.71 (-0.01), ASTM: 2.77 (-0.02)

Aastrom Biosciences Changes Name to Vericel Corporation
Marketwired - Mon Nov 24, 4:20PM CST
Aastrom Biosciences, Inc. (NASDAQ: ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to Vericel Corporation (NASDAQ: VCEL) ("Vericel"

, effective immediately. The name change has been approved by the company's shareholders. In conjunction with this change, the company has moved its headquarters to Cambridge, Massachusetts, site of its commercial manufacturing facility. Vericel also will maintain operations and several key corporate functions in Ann Arbor, Michigan.
VCEL: 3.71 (-0.01), ASTM: 2.77 (-0.02)

Aastrom Biosciences' (ASTM) CEO Nick Colangelo on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 1:42PM CST

ASTM: 2.77 (-0.02)

Aastrom Bio Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:47AM CST

ASTM: 2.77 (-0.02)

Aastrom Biosciences (ASTM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:25AM CST

ASTM: 2.77 (-0.02)

Aastrom Biosciences beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 7:21AM CST

ASTM: 2.77 (-0.02)

Aastrom Biosciences Reports Third-Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 7:16AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the quarter ended September 30, 2014. The results for the three months ended September 30, 2014 incorporate the first full quarter of operating results following the May 30, 2014 acquisition of Sanofi's cell therapy and regenerative medicine business (the acquired business).
ASTM: 2.77 (-0.02)

Aastrom Biosciences reports November 13
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:13PM CST

ASTM: 2.77 (-0.02)

Aastrom Biosciences to Host Third Quarter 2014 Earnings Call on November 13, 2014
GlobeNewswire - Wed Nov 05, 3:36PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast:
ASTM: 2.77 (-0.02)

Aastrom Biosciences proposes change in name & headquarter location
M2 - Fri Oct 10, 5:29AM CDT
Cellular therapies company Aastrom Biosciences (NasdaqCM:ASTM) said on Thursday that it intends to change its corporate name to Vericel, subject to the approval of its shareholders.
ASTM: 2.77 (-0.02)

Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts
GlobeNewswire - Thu Oct 09, 4:30PM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced plans to change its corporate name to Vericel Corporation and move its corporate headquarters to Cambridge, Massachusetts. The corporate name change is subject to the approval of Aastrom's shareholders. Aastrom will continue to maintain manufacturing facilities in Cambridge, Massachusetts and Ann Arbor, Michigan.
ASTM: 2.77 (-0.02)

Aastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the closing of its previously announced underwritten public offering of 15,784,313 shares of its common stock at a price to the public of $2.55 per share, including 2,058,823 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of approximately $40.3 million before deducting underwriting discounts and commissions and other estimated offering expenses.
ASTM: 2.77 (-0.02), LTS: 3.92 (-0.02)

Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI(TM) at the 2015 American Academy of Orthopedic Surgeons Annual Meeting
GlobeNewswire - Tue Sep 16, 9:06AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that three-year results from the SUMMIT extension study on the clinical efficacy and safety of matrix-applied characterized autologous chondrocytes (MACI(TM)) for treating cartilage defects will be presented in a poster session at the American Academy of Orthopedic Surgeons annual meeting in Las Vegas, Nevada starting on Tuesday, March 24, 2015. The poster is entitled "SUMMIT Extension: Matrix-induced Autologous Chondrocyte Implant vs Microfracture at 3 Years."
ASTM: 2.77 (-0.02)

Aastrom Biosciences prices public offering at USD2.55 per share
M2 - Fri Sep 12, 7:39AM CDT
Cellular therapies company Aastrom Biosciences (NasdaqCM:ASTM) said on Thursday that it has priced a public offering of 13,725,490 common shares at USD2.55 per share.
ASTM: 2.77 (-0.02)

Aastrom Biosciences Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Sep 11, 7:30AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has priced a public offering of 13,725,490 shares of its common stock at a price to the public of $2.55 per share. Aastrom has also granted the underwriters a 30-day option to purchase up to an additional 2,058,823 shares of common stock. The offering is expected to close on or about September 16, 2014, subject to customary closing conditions.
ASTM: 2.77 (-0.02), LTS: 3.92 (-0.02)

Market Maker Surveillance Report. ASTM, EXEL, RSH, CONN, AYSI, SGOC, Losing Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Aastrom Biosciences Inc (NASDAQ:ASTM), Exelixis Inc (NASDAQ:EXEL), RadioShack Corp (NYSE:RSH), CONN'S, INC. (NASDAQ:CONN), ALLOY STEEL INTERNATIONAL (OTC:AYSI), SOLOMON GOLD CORP (NASDAQ:SGOC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ASTM: 2.77 (-0.02), CONN: 24.69 (-0.07), SGOC: 0.56 (-0.03), RSH: 0.24 (-0.04), EXEL: 2.48 (+0.20)

Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
GlobeNewswire - Fri Aug 22, 8:15AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that results from the company's Phase 2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM) were published in the peer-reviewed journal Circulation Research. In an article entitled "Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy," results showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM.
ASTM: 2.77 (-0.02)

Aastrom Biosciences Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:30AM CDT
U.S. Commercial Business Generates Positive Contribution
ASTM: 2.77 (-0.02)

Aastrom Biosciences to Host Second Quarter 2014 Earnings Call on August 14, 2014
GlobeNewswire - Mon Aug 11, 9:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast:
ASTM: 2.77 (-0.02)

Aastrom elects Zac Taylor as national sales director
M2 - Mon Jul 14, 8:55AM CDT
Cellular therapies company Aastrom Biosciences (NasdaqCM:ASTM) revealed on Monday the election of Zac Taylor as its national sales director.
ASTM: 2.77 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...